{
    "nctId": "NCT06162663",
    "briefTitle": "Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors",
    "officialTitle": "Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Insomnia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 44,
    "primaryOutcomeMeasure": "Participant reported insomnia symptoms evaluated using the Insomnia Severity Index (ISI)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult post menopausal breast cancer survivors (female, \\> 18 years old)\n* current selective estrogen modulator or aromatase inhibitor use\n* at least 6 weeks beyond completion of definitive treatment for breast cancer\n* less than 5 years from time of diagnosis.\n\nExclusion Criteria:\n\n* less than 6-month life expectancy\n* current steroid use\n* severe depression or anxiety\n* severe hepatic impairment\n* concurrent use of moderate or strong CYP3A inhibitors\n* current receipt of hospice care\n* severe mental illness\n* current use of greater than 40 morphine milligram equivalents daily\n* diagnosis of obstructive sleep apnea, narcolepsy or other sleep related illness other than insomnia\n* pregnancy\n* treatment with alternate pharmacotherapy for insomnia at the time of trial initiation\n* menstrual cycle within the past year",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}